Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Boris Royak

Psychiatry Beachwood, OH Medical Doctor

NPI 1528091899 CMS profile 68679

25700 Science Park Dr Ste 210, Beachwood, OH 44122

Open in the dashboard

General payments

$61,902

224 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Boris Royak of Beachwood, OH is reported in the CMS Open Payments database as having received $61,902 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $228 10
2024 General $1,332 12
2023 General $121 7
2022 General $5,138 20
2021 General $9,825 25
2020 General $10,102 29
2019 General $35,156 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Boris Royak
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Boris Royak were reported at $228. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Boris Royak Psychiatry median Middle half National median
2019 $35,156 $184 $59–$605 $163
2020 $10,102 $119 $36–$372 $114
2021 $9,825 $143 $43–$576 $132
2022 $5,138 $153 $50–$590 $149
2023 $121 $170 $56–$651 $160
2024 $1,332 $179 $57–$673 $164
2025 $228 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $35,408 45 payments
  2. ACADIA Pharmaceuticals Inc $20,627 41 payments
  3. Indivior Inc. $2,466 4 payments
  4. Janssen Pharmaceuticals, Inc $1,334 13 payments
  5. Sunovion Pharmaceuticals Inc. $475 25 payments
  6. Otsuka America Pharmaceutical, Inc. $291 17 payments
  7. AbbVie, Inc. $226 18 payments
  8. Lundbeck LLC $204 11 payments
  9. Alkermes, Inc. $193 10 payments
  10. Vanda Pharmaceuticals Inc. $175 9 payments
  11. Other $502 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,032 21 payments
  2. Consulting Fee $14,600 5 payments
  3. Food and Beverage $4,636 173 payments
  4. Travel and Lodging $2,633 25 payments
Products named General payments · program years 2019–2025
  1. AUSTEDO $35,408 45 payments
  2. NUPLAZID $20,603 40 payments
  3. PERSERIS $2,466 4 payments
  4. SPRAVATO $1,257 9 payments
  5. LATUDA $475 25 payments
  6. REXULTI $229 14 payments
  7. VRAYLAR Neuroscience $226 18 payments
  8. HETLIOZ $175 9 payments
  9. FANAPT $175 9 payments
  10. VRAYLAR Neuroscience $166 14 payments
  11. Other $1,710 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

80

Median for Psychiatry: 574

Drug cost

$1,608

Median for Psychiatry: $27,624

Branded share of claims

0%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buspirone Hcl Generic 27 $587
Oxcarbazepine Generic 12 $349
Benztropine Mesylate Generic 13 $266
Mirtazapine Generic 15 $206
Sertraline Hcl Generic 13 $199

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $1,199
$1,199 — —
REXULTI
  • Lundbeck LLC $25
  • Otsuka America Pharmaceutical, Inc. $21
$45 — —
LYBALVI
  • Alkermes, Inc. $27
$27 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $17
$17 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record